Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Research And Development Expense of $12.71 million for the year ending 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +0.5% in Research And Development Expense from 2024 to 2025.
- This data is from CATALYST PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $905.6 thousand | Q3 2011: $614.1 thousand | Q1 2012: $727.3 thousand | Q2 2012: $532.7 thousand | Q3 2012: $654.8 thousand | Q1 2013: $1.09 million | Q2 2013: $2.13 million | Q3 2013: $2.80 million | Q1 2014: $2.75 million | Q2 2014: $2.10 million | Q3 2014: $2.89 million | Q1 2015: $2.35 million | Q2 2015: $2.58 million | Q3 2015: $3.04 million | Q1 2016: $3.55 million | Q2 2016: $2.51 million | Q3 2016: $2.49 million | Q1 2017: $2.81 million | Q2 2017: $2.45 million | Q3 2017: $2.70 million | Q1 2018: $3.26 million | Q2 2018: $3.70 million | Q3 2018: $4.54 million | Q1 2019: $3.31 million | Q2 2019: $4.63 million | Q3 2019: $4.60 million | Q1 2020: $4.22 million | Q2 2020: $4.35 million | Q3 2020: $3.75 million | Q1 2021: $3.01 million | Q2 2021: $4.45 million | Q3 2021: $4.49 million | Q1 2022: $3.40 million | Q2 2022: $3.98 million | Q3 2022: $8.31 million | Q1 2023: $3.56 million | Q2 2023: $3.95 million | Q3 2023: $83.66 million | Q1 2024: $2.58 million | Q2 2024: $2.99 million | Q3 2024: $3.28 million | Q1 2025: $3.89 million | Q2 2025: $4.36 million | Q3 2025: $2.66 million.
- Over the full 17 years of available data (2009 to 2025), CATALYST PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 149.3%.
- Historical annual values: Fiscal year 2025: $12.71 million | Fiscal year 2024: $12.65 million | Fiscal year 2023: $93.15 million | Fiscal year 2022: $19.79 million | Fiscal year 2021: $16.94 million | Fiscal year 2020: $16.50 million | Fiscal year 2019: $18.84 million | Fiscal year 2018: $19.92 million | Fiscal year 2017: $11.38 million | Fiscal year 2016: $11.37 million | Fiscal year 2015: $11.80 million | Fiscal year 2014: $10.12 million | Fiscal year 2013: $8.10 million | Fiscal year 2012: $2.66 million | Fiscal year 2011: $3.38 million | Fiscal year 2010: $2.31 million | Fiscal year 2009: $5.10 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: